J&J Scraps Antipsychotic Study .

[Guest guest]

J & J Scraps Antipsychotic Study .March 31 2011 at 9:14 AM

Anonymous

& has scrapped plans for a clinical trial comparing its injectable antipsychotic Invega Sustenna with various oral treatments, citing a "reconsideration of priorities."

J & J, of New Brunswick, N.J., disclosed the development in an update last week to a listing for the trial on the U.S. government database clinicaltrials.gov. Patient enrollment hadn't started.

The study's aim had been to compare Invega Sustenna with several oral antipsychotics including J & J's own Risperdal and AstraZeneca PLC's Seroquel in 1,000 schizophrenia patients recently discharged from psychiatric hospitals.

Researchers had planned to test whether Invega Sustenna could delay time until treatment failuredefined as re-hospitalization, suicide, discontinuation of treatment and other eventsversus the other drugs for a period up to 12 months.

J & J said in its update it withdrew the study prior to enrollment "due to an internal reconsideration of priorities of the product portfolio."

J & J spokesman Greg Panico declined to provide more details about the reasons for withdrawing the trial, but said the company remains committed to developing treatments for schizophrenia and the broader field of neuroscience.

Invega Sustenna is a once-monthly injection intended for people who have difficulty remembering to take a pill every day; it was approved by U.S. regulators in 2009. An orally administered pill formulation of Invega was approved for sale in 2006.

Invega generated sales of $424 million for 2010, up 8% from 2009.

J & J recently recalled about 70,000 syringes of Invega Sustenna after discovering cracks in the syringes that could potentially lead to infections or reduced efficacy in users.

Write to Loftus at peter.loftus@...

http://online.wsj.com/article/SB10001424052748704559904576228742195359316.html

[Guest guest]

J & J Scraps Antipsychotic Study .March 31 2011 at 9:14 AM

Anonymous

& has scrapped plans for a clinical trial comparing its injectable antipsychotic Invega Sustenna with various oral treatments, citing a "reconsideration of priorities."

J & J, of New Brunswick, N.J., disclosed the development in an update last week to a listing for the trial on the U.S. government database clinicaltrials.gov. Patient enrollment hadn't started.

The study's aim had been to compare Invega Sustenna with several oral antipsychotics including J & J's own Risperdal and AstraZeneca PLC's Seroquel in 1,000 schizophrenia patients recently discharged from psychiatric hospitals.

Researchers had planned to test whether Invega Sustenna could delay time until treatment failuredefined as re-hospitalization, suicide, discontinuation of treatment and other eventsversus the other drugs for a period up to 12 months.

J & J said in its update it withdrew the study prior to enrollment "due to an internal reconsideration of priorities of the product portfolio."

J & J spokesman Greg Panico declined to provide more details about the reasons for withdrawing the trial, but said the company remains committed to developing treatments for schizophrenia and the broader field of neuroscience.

Invega Sustenna is a once-monthly injection intended for people who have difficulty remembering to take a pill every day; it was approved by U.S. regulators in 2009. An orally administered pill formulation of Invega was approved for sale in 2006.

Invega generated sales of $424 million for 2010, up 8% from 2009.

J & J recently recalled about 70,000 syringes of Invega Sustenna after discovering cracks in the syringes that could potentially lead to infections or reduced efficacy in users.

Write to Loftus at peter.loftus@...

http://online.wsj.com/article/SB10001424052748704559904576228742195359316.html

[Guest guest]

J & J Scraps Antipsychotic Study .March 31 2011 at 9:14 AM

Anonymous

& has scrapped plans for a clinical trial comparing its injectable antipsychotic Invega Sustenna with various oral treatments, citing a "reconsideration of priorities."

J & J, of New Brunswick, N.J., disclosed the development in an update last week to a listing for the trial on the U.S. government database clinicaltrials.gov. Patient enrollment hadn't started.

The study's aim had been to compare Invega Sustenna with several oral antipsychotics including J & J's own Risperdal and AstraZeneca PLC's Seroquel in 1,000 schizophrenia patients recently discharged from psychiatric hospitals.

Researchers had planned to test whether Invega Sustenna could delay time until treatment failuredefined as re-hospitalization, suicide, discontinuation of treatment and other eventsversus the other drugs for a period up to 12 months.

J & J said in its update it withdrew the study prior to enrollment "due to an internal reconsideration of priorities of the product portfolio."

J & J spokesman Greg Panico declined to provide more details about the reasons for withdrawing the trial, but said the company remains committed to developing treatments for schizophrenia and the broader field of neuroscience.

Invega Sustenna is a once-monthly injection intended for people who have difficulty remembering to take a pill every day; it was approved by U.S. regulators in 2009. An orally administered pill formulation of Invega was approved for sale in 2006.

Invega generated sales of $424 million for 2010, up 8% from 2009.

J & J recently recalled about 70,000 syringes of Invega Sustenna after discovering cracks in the syringes that could potentially lead to infections or reduced efficacy in users.

Write to Loftus at peter.loftus@...

http://online.wsj.com/article/SB10001424052748704559904576228742195359316.html

[Guest guest]

J & J Scraps Antipsychotic Study .March 31 2011 at 9:14 AM

Anonymous

& has scrapped plans for a clinical trial comparing its injectable antipsychotic Invega Sustenna with various oral treatments, citing a "reconsideration of priorities."

J & J, of New Brunswick, N.J., disclosed the development in an update last week to a listing for the trial on the U.S. government database clinicaltrials.gov. Patient enrollment hadn't started.

The study's aim had been to compare Invega Sustenna with several oral antipsychotics including J & J's own Risperdal and AstraZeneca PLC's Seroquel in 1,000 schizophrenia patients recently discharged from psychiatric hospitals.

Researchers had planned to test whether Invega Sustenna could delay time until treatment failuredefined as re-hospitalization, suicide, discontinuation of treatment and other eventsversus the other drugs for a period up to 12 months.

J & J said in its update it withdrew the study prior to enrollment "due to an internal reconsideration of priorities of the product portfolio."

J & J spokesman Greg Panico declined to provide more details about the reasons for withdrawing the trial, but said the company remains committed to developing treatments for schizophrenia and the broader field of neuroscience.

Invega Sustenna is a once-monthly injection intended for people who have difficulty remembering to take a pill every day; it was approved by U.S. regulators in 2009. An orally administered pill formulation of Invega was approved for sale in 2006.

Invega generated sales of $424 million for 2010, up 8% from 2009.

J & J recently recalled about 70,000 syringes of Invega Sustenna after discovering cracks in the syringes that could potentially lead to infections or reduced efficacy in users.

Write to Loftus at peter.loftus@...

http://online.wsj.com/article/SB10001424052748704559904576228742195359316.html